All News

hand stopping falling dominos

Toward Long-Term Prevention of Rheumatoid Arthritis: Are We Closer?

d Jonathan Kay, MD

As earlier diagnosis and treatment of rheumatoid arthritis (RA) have resulted in greatly improved clinical outcomes, the focus of current research has now shifted to preventing the development of RA altogether. At EULAR 2025, several oral presentations explored this objective, highlighting data from three key prevention trials: APIPRA, ARIAA, and TREAT EARLIER. Each trial targeted individuals considered to be “at-risk” for developing RA, investigating whether early immunomodulatory interventions could delay or prevent progression to classifiable RA.

Read Article
smartphone

Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia

d Antoni Chan, MD, PhD

The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence and digital health technologies. At #EULAR2025, the Bechterew-App Trial (LB0002) presented important new data on Axia, a novel AI-powered digital therapeutic developed for axSpA.

Read Article
lupus,nephritis,GN

2025 update of EULAR recommendations on lupus nephritis

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented a summary of the updated EULAR recommendations on the management of lupus nephritis (LN). The most significant change in the treatment paradigm of LN is that the historic standard of care (SOC) (i.e.

Read Article
pregnant, pregnancy, mother, fertility

Pregnancy outcomes in autoinflammatory disease

d EurekAlert!

To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health.

Read Article
PsA.Hands_.jpg

From Domains to Decisions: Personalizing PsA Care with Data

d Jiha Lee, MD

At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; it’s about understanding the unique constellation of domains, comorbidities, and patient factors that shape each clinical decision.

Read Article
Psoriatic Arthritis: Hit hard and Early Two studies found no significant benefit of early biologics over standard methotrexate treatment, but they did not focus on poor prognosis cases. The SPEED trial, funded by the NIHR, aimed to compare disease activity in 192 PsA patients https://t.co/Vte0RSyszN
Dr. John Cush RheumNow ( View Tweet)
Combination treatments in Psoriatic Arthritis Psoriatic arthritis (PsA) is a complex inflammatory arthritis with multiple domains and associated comorbidities. Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half https://t.co/rSkoE236hR
Dr. John Cush RheumNow ( View Tweet)
Health inequities in rheumatology: A central theme This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases (RMDs). Across multiple sessions and studies, delegates are presenting compelling https://t.co/nmdyJYQV0B
Dr. John Cush RheumNow ( View Tweet)
Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systolic & diastolic dysfunction most common in late SSc NFC patterns. Cardiac dysfunction seen w/ low capillary density, avascular areas, cap neoangiogenesis https://t.co/M6uU6i5cW4
Dr. John Cush RheumNow ( View Tweet)
Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/mEYnAFsYQI

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/YDuUg44ebu
Dr. John Cush RheumNow ( View Tweet)
Transcranial Stimulation is Effective in Fibromyalgia A randomized, controlled clinical trial in fibromyalgia (FM) has shown the efficacy of transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain. https://t.co/kJk1R8ubqk
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

Dr. John Cush RheumNow ( View Tweet)

Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/HkMT9QEMg8
Dr. John Cush RheumNow ( View Tweet)
2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/STmuNO3c2Z
Dr. John Cush RheumNow ( View Tweet)
⌛️ Diagnostic delay in #SpA: Better with time? 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay decreased over time 🔹️Same trends across world regions & across Human Development Index categories POS0908 #EULAR2025 @RheumNow https://t.co/Y9gxQDV9KJ

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
EULAR Points to consider for the definition of D2M and TR #Psoriatic_Arthritis Presented by Dr Helena Marzo-Ortega at #EULAR2025 @RheumNow https://t.co/3LsJvSiXJV

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Sometimes you hear: “PMR dose steroids don’t really matter” Errrrr… (You wouldn’t accept this steroid exposure in any other disease. Never) #EULAR2025 POS0139 @RheumNow https://t.co/o6w2RpaGBj

Links:

David Liew drdavidliew ( View Tweet)
In the United States, IL-6R inhibitors have continued to help PMR patients get off steroids. Hopefully more use and more options mean that, in the future, PMR patients get no more steroids than PsA or RA patients #EULAR2025 POS0948 @RheumNow https://t.co/JT7gFDC5rl

Links:

David Liew drdavidliew ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×